- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00433888
Switch and Maintenance Study of Intravenous Injections of R744 to Hemodialysis Patients (Phase Ⅲ Study)
January 29, 2009 updated by: Chugai Pharmaceutical
Clinical Study of Switching From rHuEPO to R744 and Maintenance Treatment With R744 in Renal Anemia Patients on Hemodialysis (Phase Ⅲ Study)
This study will assess the efficacy and safety of intravenous R744 in renal anemia patients on hemodialysis.
Study Overview
Study Type
Interventional
Enrollment (Actual)
179
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Chubu, Japan
- Chubu Region
-
Chugoku/Shikoku, Japan
- Chugoku/Shikoku region
-
Hokkaido/Tohoku, Japan
- Hokkaido/Tohoku region
-
Kanto/Koshinetsu, Japan
- Kanto/Koshinetsu region
-
Kinki/Hokuriku, Japan
- Kinki/Hokuriku region
-
Kyusyu, Japan
- Kyusyu region
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients who have been receiving hemodialysis 3 times a week for at least 12 weeks before registration
- Patients aged ≥ 20 years at the time of obtaining consent Patients who have been receiving a rHuEPO preparation at least once a week for at least 8 weeks before registration
- Patients whose mean value of Hb concentrations determined before the first dialysis of each week within 8 weeks prior to the registration has been between ≥ 10.0 g/dL and <12.0 g/dL
Patients whose transferrin saturation has been ≥ 20 % or ferritin has been
- 100ng/mL at any one time point within 8 weeks before registration
Exclusion Criteria:
- Patients with hardly controllable hypertension (patients whose diastolic blood pressure has been ≥ 100 mmHg on more than 1/3 of the determining occasions within 12 weeks before registration)
- Patients with congestive cardiac failure (≥ Class III in NYHA cardiac function classification)
- Female patients who are pregnant, lactating, possibly pregnant or not willing to take a contraceptive measure in the period from the day of starting the treatment with the study drug to 90 days after the day of the last dose of the study drug
- Patients with complication of myocardial infarction, pulmonary infarction or cerebral infarction (excluding asymptomatic cerebral infarction)
- Patients confirmed to have serious allergy or serious drug allergy (shock, anaphylactoid symptom)
- Patients hypersensitive to a rHuEPO preparation
- Patients with malignant tumor (including hemic malignant tumor), severe infection, systemic hemic disease (osteomyelodysplasia syndrome, hemoglobinopathy, etc.), hemolytic anemia or apparent hemorrhagic lesion such as digestive tract hemorrhage
- Patients who have received an anabolic hormone preparation, testosterone enanthate or mepitiostane within 12 weeks before registration
- Patients who have received another investigational drug within 12 weeks before registration
- Patients who have received R744 before registration
- Patients whose AST(GOT) value ≥ 100 IU/L or ALT(GPT) value ≥ 100 IU/L before registration
- Patients who have received erythrocyte transfusion within the last 16 weeks before registration
- Patients for whom a surgical operation involved with heavy bleeding is planned during the study period
- In addition, patients who are judged as ineligible to participate in this study by the investigator or sub-investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
100μg/4 weeks for 8 weeks,then 25~400μg/4 weeks for 40 weeks
150μg/4 weeks for 8 weeks,then 25~400μg/4 weeks for 40 weeks
|
Experimental: 2
|
100μg/4 weeks for 8 weeks,then 25~400μg/4 weeks for 40 weeks
150μg/4 weeks for 8 weeks,then 25~400μg/4 weeks for 40 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of patients who maintain Hb concentration in the range of ≥ 10.0g/dL and ≤ 12.0g/dL
Time Frame: 48 weeks
|
48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse events
Time Frame: 48 weeks
|
48 weeks
|
Slope of regression line of Hb concentration (g/dL/week)
Time Frame: 48 weeks
|
48 weeks
|
Rate of patients who maintain Hb concentration in the range of ≥ 10.0g/dL and < 13.0g/dL
Time Frame: 48 weeks
|
48 weeks
|
Laboratory measurements
Time Frame: 48 weeks
|
48 weeks
|
Anti-R744 antibody titer
Time Frame: 48 weeks
|
48 weeks
|
Vital signs, standard 12-lead ECG
Time Frame: 48 weeks
|
48 weeks
|
Rate of patients who maintain Hb concentration in the range of baseline* ± 1.0g/dL
Time Frame: 48 weeks
|
48 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Takanori Baba, Clinical Research Department 2
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2007
Primary Completion (Actual)
July 1, 2008
Study Completion (Actual)
October 1, 2008
Study Registration Dates
First Submitted
February 9, 2007
First Submitted That Met QC Criteria
February 9, 2007
First Posted (Estimate)
February 12, 2007
Study Record Updates
Last Update Posted (Estimate)
February 2, 2009
Last Update Submitted That Met QC Criteria
January 29, 2009
Last Verified
January 1, 2009
More Information
Terms related to this study
Other Study ID Numbers
- JH20563
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemodialysis Patients
-
Chugai PharmaceuticalCompleted
-
Ataturk UniversityRecruiting
-
Mansoura UniversityNot yet recruitingHemodialysis Patients
-
Taipei Medical UniversityUnknown
-
Nantes University HospitalCompleted
-
Ain Shams UniversityNot yet recruitingHemodialysis Patients
-
Institut Phoceen de NephrologieRecruiting
-
Dong-A ST Co., Ltd.CompletedThe Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis PatientsHemodialysis PatientsKorea, Republic of
-
Hospital de Clinicas de Porto AlegreUnknown
-
Sohag UniversityNot yet recruitingPediatric Patients on HemodialysisEgypt
Clinical Trials on R744
-
Chugai PharmaceuticalCompleted
-
Chugai PharmaceuticalCompleted
-
Chugai PharmaceuticalCompleted
-
Chugai PharmaceuticalCompleted
-
Chugai PharmaceuticalCompleted